Lineage Cell Therapeutics (LCTX) 10-Q 9 Nov 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 06, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	BIOTIME INC
Entity Central Index Key	876,343
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		94,894,152
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
CURRENT ASSETS
Cash and cash equivalents	$ 29,378	$ 29,487
Trade accounts and grants receivable, net	944	1,042
Inventory	260	266
Landlord receivable	1,525	378
Loan receivable	506	0
Prepaid expenses and other current assets	1,752	1,232
Total current assets	34,365	32,405
Equipment, net and construction in progress	6,781	2,858
Deferred license fees	352	337
Deposits and other long-term assets	455	453
Intangible assets, net	34,906	38,848
TOTAL ASSETS	76,859	74,901
CURRENT LIABILITIES
Accounts payable and accrued liabilities	7,793	6,803
Capital lease liability, current portion	46	58
Promissory notes, current portion	95	0
Related party convertible debt, net of discount	255	60
Deferred grant income	1,869	0
Deferred license and subscription revenue, current portion	278	208
Total current liabilities	10,336	7,129
LONG-TERM LIABILITIES
Deferred tax liabilities, net	1,119	4,515
Deferred rent liabilities, net of current portion	95	97
Lease liability	4,089	378
Capital lease, net of current portion	0	31
Promissory notes, net of current portion	268	0
Other long-term liabilities	18	28
Total long-term liabilities	$ 5,589	$ 5,049
Commitments and contingencies (Note 8)
SHAREHOLDERS' EQUITY
Series A convertible preferred stock, no par value, authorized 2,000 shares as of September 30, 2015 and December 31, 2014; none and 70 issued and outstanding as of September 30, 2015 and December 31, 2014, respectively	$ 0	$ 3,500
Common stock, no par value, authorized 125,000 shares as of September 30, 2015 and December 31, 2014; 86,764 issued and 82,045 outstanding as of September 30, 2015 and 83,122 issued and 78,228 outstanding at December 31, 2014	248,069	234,850
Accumulated other comprehensive income/(loss)	(87)	186
Accumulated deficit	(215,757)	(182,190)
Treasury stock at cost: 4,719 and 4,894 shares at September 30, 2015 and at December 31, 2014, respectively	(19,182)	(19,890)
BioTime, Inc. shareholders' equity	13,043	36,456
Non-controlling interest	47,891	26,267
Total shareholders' equity	60,934	62,723
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 76,859	$ 74,901

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares shares in Thousands	Sep. 30, 2015	Dec. 31, 2014
SHAREHOLDERS' EQUITY
Series A convertible preferred stock, par value (in dollars per share)	$ 0	$ 0
Series A convertible preferred stock, authorized (in shares)	2,000	2,000
Series A convertible preferred stock, issued (in shares)	70	70
Series A convertible preferred stock outstanding (in shares)	70	70
Common stock, par value (in dollars per share)	$ 0	$ 0
Common stock, authorized (in shares)	125,000	125,000
Common stock, issued (in shares)	86,764	83,122
Common stock, outstanding (in shares)	82,045	78,228
Treasury stock (in shares)	4,719	4,894

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
REVENUES:
Subscription and advertisement revenues	$ 343	$ 285	$ 1,020	$ 880
Royalties from product sales	357	148	631	322
Grant income	1,466	648	3,596	1,863
Sale of research products and services	140	110	328	300
Total revenues	2,306	1,191	5,575	3,365
Cost of sales	(432)	(231)	(957)	(614)
Gross profit	1,874	960	4,618	2,751
OPERATING EXPENSES:
Research and development	(11,433)	(8,836)	(29,816)	(26,268)
General and administrative	(7,545)	(4,262)	(18,911)	(12,764)
Total operating expenses	(18,978)	(13,098)	(48,727)	(39,032)
Loss from operations	(17,104)	(12,138)	(44,109)	(36,281)
OTHER INCOME/(EXPENSE):
Interest expense, net	(12)	(7)	(207)	(30)
Other income/(expense), net	(573)	(119)	(408)	157
Total other income/(expense), net	(585)	(126)	(615)	127
LOSS BEFORE INCOME TAX BENEFIT	(17,689)	(12,264)	(44,724)	(36,154)
Deferred income tax benefit	948	2,313	3,395	5,175
NET LOSS	(16,741)	(9,951)	(41,329)	(30,979)
Net loss attributable to non-controlling interest	3,115	1,683	7,762	5,151
NET LOSS ATTRIBUTABLE TO BIOTIME, INC.	(13,626)	(8,268)	(33,567)	(25,828)
Preferred stock dividend	(363)	(34)	(415)	(34)
NET LOSS ATTRIBUTABLE TO BIOTIME, INC. COMMON SHAREHOLDERS	$ (13,989)	$ (8,302)	$ (33,982)	$ (25,862)
BASIC AND DILUTED NET LOSS PER COMMON SHARE (in dollars per share)	$ (0.18)	$ (0.12)	$ (0.43)	$ (0.41)
WEIGHTED AVERAGE NUMBER OF COMMON STOCK OUTSTANDING: BASIC AND DILUTED (in shares)	79,224	67,921	78,619	62,594

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) [Abstract]
NET LOSS	$ (16,741)	$ (9,951)	$ (41,329)	$ (30,979)
Change in foreign currency translation and other comprehensive income/(loss) from equity investments:
Foreign currency translation gain/(loss)	44	(67)	(273)	(216)
Unrealized loss on available-for-sale securities, net of taxes	0	(1)	0	(3)
COMPREHENSIVE LOSS	(16,697)	(10,019)	(41,602)	(31,198)
Less: Comprehensive loss attributable to non-controlling interest	(3,115)	(1,683)	(7,762)	(5,151)
COMPREHENSIVE LOSS ATTRIBUTABLE TO BIOTIME, INC. BEFORE PREFERRED STOCK DIVIDEND	(13,582)	(8,336)	(33,840)	(26,047)
Preferred stock dividend	(363)	(34)	(415)	(34)
COMPREHENSIVE LOSS ATTRIBUTABLE TO BIOTIME, INC. COMMON SHAREHOLDERS	$ (13,945)	$ (8,370)	$ (34,255)	$ (26,081)

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss attributable to BioTime, Inc.	$ (33,567)	$ (25,828)
Net loss allocable to non-controlling interest	(7,762)	(5,151)
Adjustments to reconcile net loss attributable to BioTime, Inc. to net cash used in operating activities:
Depreciation expense	776	794
Amortization of intangible assets	3,942	4,104
Amortization of deferred consulting fees	0	19
Amortization of deferred license fees	85	82
Amortization of prepaid rent in common stock	63	42
Stock-based compensation	7,189	3,321
Amortization of discount on related party convertible debt	182	4
Loss on sale or write-off of equipment	0	9
Write-off for uncollectible receivables	0	(16)
Deferred income tax benefit	(3,395)	(5,175)
Contingently issuable subsidiary warrants in lieu of investor relations expenses	65	0
Changes in operating assets and liabilities:
Accounts receivable, net	(114)	(86)
Grant receivable	212	66
Inventory	6	(75)
Prepaid expenses and other current assets	(621)	(114)
Other long-term assets	(100)	0
Accounts payable and accrued liabilities	512	(1,545)
Accrued interest on related party convertible debt	14	1
Other long-term liabilities	(9)	(124)
Deferred grant income	1,869	0
Deferred rent liabilities	(2)	(14)
Lease liability, noncurrent	(12)	0
Deferred revenues	70	(58)
Net cash used in operating activities	(30,597)	(29,744)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of equipment	(514)	(497)
Payments on construction in progress	(3,830)	0
Loan receivable	(500)	0
Proceeds from the sale of equipment	0	4
Security deposit paid, net	(9)	(306)
Cash used in investing activities	(4,853)	(799)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercises of stock options	621	220
Proceeds from sale of preferred stock	0	3,500
Proceeds from issuance of common shares	8,578	14,724
Fees paid on sale of common shares	0	(298)
Proceeds from exercise of warrants	19	0
Proceeds from exercise of subsidiary stock options	27	0
Proceeds from sale of treasury shares	576	0
Proceeds from exercise of subsidiary warrants	11,700	0
Proceeds from sale of treasury shares and issuance of subsidiary warrants	0	13,582
Proceeds from sale of subsidiary common shares	11,586	468
Fees paid on sale of subsidiary common shares	(597)	0
Reimbursement from landlord on construction in progress	2,564	0
Proceeds from issuance of related party convertible debt	188	467
Repayment of capital lease obligation	(31)	(13)
Net cash provided by financing activities	35,231	32,650
Effect of exchange rate changes on cash and cash equivalents	110	(186)
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS	(109)	1,921
CASH AND CASH EQUIVALENTS:
At beginning of the period	29,487	5,495
At end of the period	$ 29,378	$ 7,416

Organization, Basis of Presenta

Organization, Basis of Presentation, and Liquidity	9 Months Ended
	Sep. 30, 2015
Organization, Basis of Presentation, and Liquidity [Abstract]
Organization, Basis of Presentation, and Liquidity	1. Organization, Basis of Presentation, and Liquidity General – HyStem ® Renevia ESI BIO ESI BIO GeneCards ® GeneCards ® LifeMap Discovery ® MalaCards VarElect GeneAnalytics BioTime is focusing a portion of its efforts in the field of regenerative medicine on the development and sale of advanced human stem cell products and technologies that can be used by researchers at universities and other institutions, at companies in the bioscience and biopharmaceutical industries, and at other companies that provide research products to companies in those industries. These products are developed internally or in conjunction with BioTime’s subsidiaries and marketed through BioTime’s ESI BIO Until 2008, BioTime principally developed blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment and other applications. BioTime’s operating revenues are now derived primarily from research grants, from licensing fees and advertising from the marketing of the LifeMap Sciences database products, and from the sale of products for research. The unaudited condensed consolidated interim balance sheet as of September 30, 2015, the unaudited condensed consolidated interim statements of operations and statements of comprehensive loss for the three and nine months ended September 30, 2015 and 2014, and the unaudited condensed consolidated interim statements of cash flows for the nine months ended September 30, 2015 and 2014 have been prepared by BioTime’s management in accordance with the instructions from Form 10-Q and Regulation S-X. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at September 30, 2015 have been made. The consolidated balance sheet as of December 31, 2014 is derived from the Company’s annual audited financial statements as of that date. The results of operations for the three and nine months ended September 30, 2015 are not necessarily indicative of the operating results anticipated for any other interim period or for the full year of 2015. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted as permitted by regulations of the Securities and Exchange Commission (“SEC”) except for the consolidated balance sheet as of December 31, 2014, which was derived from audited financial statements. Certain previously furnished amounts have been reclassified to conform to presentations made during the current periods. These condensed consolidated interim financial statements should be read in conjunction with the annual audited consolidated financial statements and notes thereto included in BioTime’s Annual Report on Form 10-K for the year ended December 31, 2014, the audited annual financial statements of OncoCyte for the year ended December 31, 2014 filed in a registration statement on Form 10 on October 7, 2015, and the OncoCyte unaudited condensed interim financial statements as of, and for the six months ended, June 30, 2015 filed in a registration statement on Form 10 on October 7, 2015 (see Note 12). Use of estimates Principles of consolidation Subsidiary Field of Business BioTime Ownership Country Asterias Biotherapeutics, Inc. (NYSE MKT: AST) Therapeutic products derived from pluripotent stem cells, and immunotherapy products. Clinical programs include: AST-OPC1 for spinal cord injury, AST-VAC1 for acute mylegenous leukemia, and AST-VAC2 for non-small cell lung cancer 58.0% USA Cell Cure Neurosciences Ltd. Products to treat age related macular degeneration (“AMD”) and neurological diseases. Lead product OpRegen ® 62.5% (1) Israel ES Cell International Pte Ltd Stem cell products for research, including clinical grade cell lines produced under cGMP 100% Singapore LifeMap Sciences, Inc. Biomedical, gene, disease, and stem cell databases and tools 77.9% USA LifeMap Sciences, Ltd. Biomedical, gene, disease, and stem cell databases and tools (2) Israel LifeMap Solutions, Inc. Mobile health software applications (2) USA OncoCyte Corporation (4) Developing proprietary non-invasive, liquid biopsy and diagnostics for lung, breast and bladder cancers 74.9% USA OrthoCyte Corporation Orthopedic diseases and injuries, including bone grafting, chronic back pain and osteoarthritis 100.0% (3) USA ReCyte Therapeutics, Inc. Research and development involved in stem cell-derived endothelial and cardiovascular related progenitor cells for the treatment of vascular disorders, ischemic conditions and brown adipocytes for type-2 diabetes and obesity 94.8% USA (1) Includes shares owned by BioTime, Asterias, and ESI. (2) LifeMap Sciences, Ltd. and LifeMap Solutions, Inc. are wholly-owned subsidiaries of LifeMap Sciences, Inc. (3) Includes shares owned by BioTime and Asterias. (4) See Note 12 regarding OncoCyte’s O ctober 7, 2015, filing of a registration statement on Form 10 with the SEC in connection with BioTime’s planned distribution of shares of OncoCyte common stock to holders of BioTime common shares, on a pro rata basis . All material intercompany accounts and transactions have been eliminated in consolidation. As of September 30, 2015, BioTime consolidated Asterias, ReCyte Therapeutics, OncoCyte, OrthoCyte, ESI, Cell Cure Neurosciences, BioTime Asia, Limited (“BioTime Asia”), LifeMap Sciences, LifeMap Sciences, Ltd., and LifeMap Solutions as BioTime has the ability to control their operating and financial decisions and policies through its ownership, and the non-controlling interest is reflected as a separate element of shareholders' equity on BioTime’s consolidated balance sheets. Liquidity Certain significant risks and uncertainties

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2015
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Revenue recognition Cash and cash equivalents Trade accounts and grants receivable, net Concentrations of credit risk Inventory – Equipment, net and construction in progress Intangible assets, net Treasury stock – Warrants to purchase common stock Cost of sales Patent costs – Reclassification Research and development General and administrative Foreign currency translation and other comprehensive loss, foreign currency transaction gains and losses – For transactions denominated in other than the functional currency of BioTime, transactional gains and losses are recorded in other income and expense included in the condensed consolidated statements of operations. Foreign currency transaction loss amounted to $430,000 and $353,000, respectively, for the three and nine months ended September 30, 2015, and an $88,000 loss and $92,000 gain, respectively for the three and nine months ended September 30, 2014. Income taxes – An income tax benefit of approximately $3.4 million was recorded for the nine months ended September 30, 2015, of which approximately $3.6 million of the benefit was related to federal, offset by $214,000 related to state taxes. For the same period in 2014, an income tax benefit of approximately $5.2 million was recorded, of which approximately $3.6 million of the benefit was related to federal and $1.6 million to state taxes. Asterias established deferred tax liabilities primarily related to its acquisition of certain intellectual property. It is more likely than not that the Asterias deferred tax assets are fully realizable since these income tax benefits are expected to be available to offset such Asterias deferred tax liabilities. In June 2014, Asterias sold 5,000,000 BioTime shares that resulted in a taxable gain of approximately $10.3 million and a tax payable of $3.6 million. Asterias received the BioTime shares from BioTime as part of the consideration for the Asterias common stock and warrants issued to BioTime under an Asset Contribution Agreement among BioTime, Asterias, and Geron Corporation, a tax free transaction. This income tax liability was offset by available net operating losses, resulting in no cash income taxes due from that sale. This transaction was treated as a deemed distribution by Asterias and recorded against equity. During the first six months of 2014, OncoCyte sold 86,156 BioTime common shares in open market transactions that resulted in a taxable gain of approximately $300,000. This taxable gain was fully offset by current operating losses, thus resulting in no income taxes due from the sale. A valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. OncoCyte established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. Stock-based compensation – Impairment of long-lived assets – Deferred license fees Loss per share Fair value of financial instruments Recently Issued Accounting Pronouncements In July 2015, the FASB postponed the effective date of the new revenue standard, Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606),” by one year. The new effective date is for fiscal years and interim periods beginning after December 15, 2017. BioTime expects to adopt this guidance when effective and the impact, if any, on its consolidated financial statements is not currently estimable. In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory” that replaces the existing accounting standards for the measurement of inventory. ASU 2015-11 requires a company to measure inventory at the lower of cost and net realizable value. Net realizable value is defined as the “estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation.” The effective date of ASU 2015-11 is for annual reporting periods beginning after December 15, 2016, including interim periods within those annual reporting periods. BioTime does not expect ASU 2015-11 will have a material effect on its consolidated financial statements.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2015
Inventory [Abstract]
Inventory	3. Inventory, net BioTime held $247,000 and $253,000 of raw materials and finished goods products on-site at its corporate headquarters in Alameda, California at September 30, 2015 and December 31, 2014, respectively. Finished goods products of $13,000 were held by a third party on consignment at September 30, 2015 and December 31, 2014.

Equipment, net and construction

Equipment, net and construction in progress	9 Months Ended
	Sep. 30, 2015
Equipment, net and construction in progress [Abstract]
Equipment, net and construction in progress	4. Equipment, net and construction in progress At September 30, 2015 and December 31, 2014, equipment, furniture and fixtures, and construction in progress were comprised of the following (in thousands): September 30, 2015 (Unaudited) December 31, 2014 Equipment, furniture and fixtures $ 5,383 $ 4,871 Construction in progress 4,604 406 Accumulated depreciation (3,206 ) (2,419 ) Equipment, net and construction in progress $ 6,781 $ 2,858 Depreciation expense amounted to $776,000 and $794,000 for the nine months ended September 30, 2015 and 2014, respectively. Construction in progress Construction in progress of $4.6 million as of September 30, 2015 entirely relates to the improvements for Asterias' Fremont facility. Under the terms of the lease agreement, the landlord has provided Asterias with a tenant improvement allowance of up to $4.4 million, which Asterias is using to construct a laboratory and production facility that can be used to produce human embryonic stem cell and related products under cGMP. Of the $4.6 million, $4.1 million qualifies for reimbursement under the tenant improvement allowance with $0.3 million remaining under this allowance. As of September 30, 2015, Asterias received $2.6 million from the landlord. Reimbursable amounts due to Asterias but not yet paid by the landlord as of period end are recorded as a landlord receivable with a corresponding increase to lease liability since Asterias has contractually earned the right to receive that payment. The facility is expected to be substantially completed and placed into service in the fourth quarter of 2015.

Intangible assets, net

Intangible assets, net	9 Months Ended
	Sep. 30, 2015
Intangible assets, net [Abstract]
Intangible assets, net	5. Intangible assets, net At September 30, 2015 and December 31, 2014, intangible assets were comprised of the following (in thousands): September 30, 2015 (Unaudited) December 31, 2014 Intangible assets $ 52,562 $ 52,562 Accumulated amortization (17,656 ) (13,714 ) Intangible assets, net $ 34,906 $ 38,848 BioTime amortizes its intangible assets generally over an estimated period of 10 years on a straight-line basis. BioTime recognized $3.9 million and $4.1 million in amortization expense of intangible assets, included in research and development, during the nine months ended September 30, 2015 and 2014, respectively.

Deferred License Fees

Deferred License Fees	9 Months Ended
	Sep. 30, 2015
Deferred License Fees [Abstract]
Deferred License Fees	6. Deferred License Fees BioTime amortizes deferred license fees over the estimated useful lives of the licensed technologies or licensed research products. BioTime is applying a 10 year estimated useful life to the technologies and products that it is currently licensing. The estimation of the useful life of any technology or product involves a significant degree of inherent uncertainty, since the outcome of research and development or the commercial life a new product cannot be known with certainty at the time that the right to use the technology or product is acquired. BioTime periodically reviews its amortization schedules for impairments that might occur earlier than the original expected useful lives. As of September 30, 2015, future amortization of deferred license fees described above was as follows (in thousands): Year Ended December 31, Deferred License Fees 2015 $ 34 2016 125 2017 120 2018 83 2019 34 Thereafter 75 Total $ 471 The current portion in the amount of $119,000 is included in prepaid expenses and other current assets. The noncurrent portion in the amount of $352,000 is included in deferred license fees.

Accounts Payable and Accrued Li

Accounts Payable and Accrued Liabilities	9 Months Ended
	Sep. 30, 2015
Accounts Payable and Accrued Liabilities [Abstract]
Accounts Payable and Accrued Liabilities	7. Accounts Payable and Accrued Liabilities At September 30, 2015 and December 31, 2014, accounts payable and accrued liabilities consisted of the following (in thousands): September 30, 2015 (Unaudited) December 31, 2014 Accounts payable $ 1,934 $ 2,297 Accrued expenses 4,729 3,125 Accrued bonuses 804 964 Other current liabilities 326 417 Total $ 7,793 $ 6,803

Commitments and Related Party T

Commitments and Related Party Transactions	9 Months Ended
	Sep. 30, 2015
Commitments Related Party Transactions and Related Party Convertible Debt Abstract [Abstract]
Commitments, Related Party Transactions and Related Party Convertible Debt	8. Commitments and Related Party Transactions BioTime currently pays $5,050 per month for the use of approximately 900 square feet of office space in New York City, which is made available to BioTime on a month-by-month basis by one of its directors at an amount that approximates his cost. During June 2014, Asterias sold 5,000,000 of its BioTime common shares with warrants to purchase 5,000,000 shares of Asterias common stock to two investors for $12.5 million in cash. Broadwood Partners, L.P. (“Broadwood”), purchased 1,000,000 of the BioTime common shares with 1,000,000 Asterias warrants and a trust previously established by George Karfunkel purchased 4,000,000 of the BioTime common shares with 4,000,000 Asterias warrants. Asterias received $11.7 million when the warrants were exercised in May 2015. Broadwood is BioTime’s largest shareholder and one of its directors, Neal C. Bradsher, is President, and one of Asterias’ directors, Richard T. LeBuhn, is Senior Vice President, of Broadwood Capital, Inc., the investment manager of Broadwood. In February 2015, Asterias raised approximately $5.5 million in aggregate gross proceeds from the sale of 1,410,255 shares of its common stock at a price of $3.90 per share through an underwritten public offering and a private placement. Broadwood, British & American Investment Trust PLC and Pedro Lichtinger purchased an aggregate of 1,025,640 of the shares. Pedro Lichtinger is Asterias’ Chief Executive Officer and a member of its Board of Directors. British & American Investment Trust PLC is an affiliate of a stockholder of Asterias and BioTime. In April 2015, Cell Cure Neurosciences issued certain convertible notes (the “Convertible Notes”) to a Cell Cure Neurosciences shareholder other than BioTime in the principal amount of $188,000. In July and September 2014, Cell Cure Neurosciences issued Convertible Notes to two Cell Cure Neurosciences shareholders other than BioTime in the principal amount of $471,000. One of the Cell Cure Neurosciences shareholders who acquired Convertible Notes is considered a related party. The functional currency of Cell Cure Neurosciences is the Israeli New Shekel, however the Convertible Notes are payable in United States dollars. The Convertible Notes bear a stated interest rate of 3% per annum. The total outstanding principal balance of the Convertible Notes, with accrued interest, is due and payable on various maturity dates in July and September 2017. The outstanding principal balance of the Convertible Notes with accrued interest is convertible into Cell Cure Neurosciences ordinary shares at a fixed conversion price of $20.00 per share, at the election of the holder, at any time prior to maturity. Any conversion of the Convertible Notes must be settled with Cell Cure Neurosciences ordinary shares and not with cash. The conversion feature of the Convertible Notes is not accounted for as an embedded derivative under the provisions of ASC 815, Derivatives and Hedging Debt with Conversion and Other Options. In May 2015, OncoCyte entered into Subscription Agreements with two of its investors (the “Investors”) and BioTime (the “Subscription Agreements”). Under the Subscription Agreements, OncoCyte sold 3,000,000 shares of its common stock for $3.3 million in cash to the Investors, 1,000,000 shares of which were sold to George Karfunkel, a beneficial owner of more than 5% of the outstanding common shares of BioTime. In June 2015, after the sale of stock under the Subscription Agreements described above was completed, OncoCyte and the Investors entered into a second agreement. Under the second agreement, the Investors agreed that if on or before June 30, 2016 OncoCyte conducts another rights offering to its shareholders at a pre-offer valuation of at least $40.0 million the Investors will purchase shares in that offering with an aggregate purchase price equal to the lesser of (a) a percentage of total amount of capital which OncoCyte then seeks to raise in the rights offer and in any concurrent offering to third parties equal to the Investors’ aggregate pro rata share of the outstanding OncoCyte common stock on the record date for the rights offering, determined on a fully diluted basis, and (b) $3.0 million, or such lesser amount requested by OncoCyte. Under the second agreement, OncoCyte agreed that if shares of OncoCyte common stock are not publicly traded on any stock exchange or over the counter market by January 15, 2016, OncoCyte will issue to the Investors, warrants to purchase, in the aggregate, 3,000,000 shares of OncoCyte common stock at an exercise price of $0.01 per share. If issued, the warrants will expire on December 31, 2016. See Note 12. The Investors also agreed that, for a period of one year from the date of the second agreement, neither of them shall invest or engage, directly or indirectly, whether as a partner, equity holder, lender, principal, agent, affiliate, consultant or otherwise, in any business anywhere in the world that develops products for the diagnosis and treatment of cancer or otherwise competes with OncoCyte in any way; provided, however, that the passive ownership of less than 5% of the outstanding stock of any publicly-traded corporation will not be deemed, solely by reason thereof, to be in violation of that agreement. For accounting purposes, the contingently issuable warrants, under the second agreement described above, are considered issued in June 2015 and classified as equity. OncoCyte estimated the issue date fair value of the warrants using a Black-Scholes valuation model and management believes that there is a low probability of not satisfying the contingency and having to issue the warrants. Accordingly, the probability-adjusted, fair value of the warrants was $65,400 on the issuance date and recognized as a general and administrative expense, with a corresponding increase to common stock equity. Since the warrants are classified as equity and are considered issued for accounting purposes as of June 30, 2015, no further remeasurement of the warrants’ fair value has been made in subsequent periods for financial statement reporting purposes. In September 2015, BioTime sold 2,607,401 common shares at an offering price of $3.29 per share, for an aggregate purchase price of $8.6 million. Broadwood purchased The price per share was the closing price of the common shares on the NYSE MKT on September 11, 2015, the last trading day before BioTime and the investors entered into purchase agreements for the sale of the shares. BioTime used $8.35 million of the proceeds to purchase additional shares of OncoCyte common stock through a subscription rights offer made by OncoCyte to its stockholders.

Shareholders' Equity

Shareholders' Equity	9 Months Ended
	Sep. 30, 2015
Shareholders' Equity [Abstract]
Shareholders' Equity	9. Shareholders’ Equity Preferred Shares BioTime is authorized to issue 2,000,000 shares of preferred stock. The preferred shares may be issued in one or more series as the board of directors may by resolution determine. The board of directors is authorized to fix the number of shares of any series of preferred shares and to determine or alter the rights, preferences, privileges, and restrictions granted to or imposed on the preferred shares as a class, or upon any wholly unissued series of any preferred shares. The board of directors may, by resolution, increase or decrease (but not below the number of shares of such series then outstanding) the number of shares of any series of preferred shares subsequent to the issue of shares of that series. In August 2015, to accommodate BioTime’s listing application to the Tel Aviv Stock Exchange (the “TASE”) BioTime and the BioTime preferred stock holders entered into a Preferred Stock Conversion Agreement (“PSCA”) whereby all of the 70,000 shares of Series A convertible preferred stock (“Series A Preferred Stock”) were converted into BioTime common shares at a conversion price of $4.00 per share, a conversion ratio of 12.5 common shares for each share of Series A Preferred Stock. In connection with the PSCA BioTime delivered to the holders of the Series A Preferred Stock promissory notes for the net present value amount of the 3% dividends that the Series A Preferred Stock holders would have received if they held their shares of Series A Preferred Stock until March 4, 2019 (the mandatory conversion date under the terms of the Series A Preferred Stock) rather than converting those shares into common shares during August 2015. Payments of principal and interest on the promissory notes will be made semi-annually, from July 2015 through March 4, 2019. The issuance date fair value of the promissory notes was approximately $363,000, representing the net present value of cash payments to be made to the former preferred stock holders under the terms of the promissory notes. In connection with the original issuance of the Series A Preferred Stock, BioTime entered into Option Agreements with the purchasers of the Series A Preferred Stock granting them the option to exchange shares of their Series A Preferred Stock for a portion of the shares of LifeMap Sciences common stock held by BioTime ("Original Option"). Pursuant to the PSCA, BioTime agreed that the former holders of Series A Preferred Stock may tender BioTime common shares in lieu of Series A Preferred Stock if they elect to exercise their option to acquire shares of LifeMap Sciences common stock from BioTime ("PSCA Option"). BioTime accounted for the PSCA as an induced conversion of preferred stock in accordance with ASC 260-10-S99-2, Earnings Per Share – SEC Materials Common Shares BioTime is authorized to issue 125,000,000 common shares with no par value. As of September 30, 2015, BioTime had 86,763,528 issued and 82,044,586 outstanding common shares. As of December 31, 2014, BioTime had 83,121,698 issued and 78,227,756 outstanding common shares. The difference of 4,718,942 and 4,893,942 common shares as of September 30, 2015 and December 31, 2014, respectively is attributed to shares held by BioTime subsidiaries that are accounted for as treasury stock on the condensed consolidated balance sheet. During the nine months ended September 30, 2015 and 2014, BioTime granted 1,100,000 and 1,410,000 options, respectively, under its 2012 Equity Incentive Plan. During the nine months ended September 30, 2015, 155,532 options and 3,897 warrants were exercised for gross proceeds of $621,000 and $19,000, respectively.

Sales of BioTime Common Shares

Sales of BioTime Common Shares by Subsidiaries	9 Months Ended
	Sep. 30, 2015
Sales of BioTime Common Shares by Subsidiaries [Abstract]
Sales of BioTime Common Shares by Subsidiaries	10. Sales of BioTime Common Shares by Subsidiaries Certain BioTime subsidiaries hold BioTime common shares that the subsidiaries received from BioTime in exchange for capital stock in the subsidiaries. The BioTime common shares held by subsidiaries are treated as treasury stock by BioTime and BioTime does not recognize a gain or loss on the sale of those shares by its subsidiaries. During September 2015 certain BioTime subsidiaries sold 175,000 BioTime common shares for gross proceeds of $576,000 at the prevailing market price. The proceeds of the sale of BioTime shares by BioTime’s subsidiaries belong to those subsidiaries. During June 2014, Asterias sold 5,000,000 of its BioTime common shares with warrants to purchase 5,000,000 shares of Asterias common stock to two investors for $12.5 million in cash. See Note 8.

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2015
Segment Information [Abstract]
Segment Information	11. Segment Information BioTime’s executive management team, as a group, represents the entity’s chief operating decision makers. To date, BioTime’s executive management team has viewed BioTime’s operations as one segment that includes, the research and development of therapeutic products for oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer, and hydrogel products that may be used in in the delivery of cell therapies and other bioactive substances, and products for human embryonic stem cell research. As a result, the financial information disclosed materially represents all of the financial information related to BioTime’s sole operating segment.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent Events Effective September 8, 2015, BioTime common shares were approved for listing on the TASE and are now dual listed on the TASE and NYSE MKT. In connection with the TASE listing, BioTime common shares are now included in certain TASE stock indexes. During October 2015, BioTime sold 6,530,612 common shares for $20.4 million in the aggregate to certain investment funds in Israel that hold shares of companies that are included within certain stock indexes of the TASE. The $3.13 purchase price per share was determined with reference to the closing price of BioTime common shares on the TASE on the date of sale. In addition, OncoCyte sold 246,356 BioTime common shares at the same price to one of the Israeli investment funds. In October 2015, BioTime sold 1,600,000 common shares to Broadwood for $5.1 million. The $3.19 price of price per share was the closing price of the common shares on the NYSE MKT on October 1, 2015, the last trading day before BioTime and Broadwood entered into a purchase agreement for the sale of the shares. On October 7, 2015, OncoCyte filed a registration statement on Form 10 with the SEC in connection with BioTime’s planned distribution of shares of OncoCyte common stock to holders of BioTime common shares, on a pro rata basis. BioTime’s board of directors has not yet determined the number of shares of OncoCyte common stock to distribute, the record date for determining holders of BioTime common shares entitled to receive OncoCyte common stock in the distribution, or the date on which the distribution will take place. On October 8, 2015, Asterias entered into a Services Agreement (the "Services Agreement") with Cell Therapy Catapult Services Limited ("Catapult"), a research organization specializing in the development of technologies which speed the growth of the cell and gene therapy industry. Under the Services Agreement, Catapult will license to Asterias, certain background intellectual property (the "License") and will develop a scalable manufacturing and differentiation process for Asterias' human embryonic stem cell derived AST-VAC2 allogeneic (non-patient specific) dendritic cancer vaccine development program. In consideration for the License and Catapult's performance of services, Asterias agreed to make aggregate payments of up to GBP £4,350,000 (approximately $6.6 million based on the foreign currency exchange rates on October 8, 2015) over the next five years. At the option of Asterias, up to GBP £3,600,000 (approximately up to $5.5 million based on the foreign currency exchange rates on October 8, 2015) of such payments may be settled in shares of Asterias Series A Common Stock. On November 5, 2015 BioTime, ESI and ReCyte Therapeutics entered into an Asset Contribution Agreement with Hepregen, Inc. (“Hepregen”) related to the organization of a new company, Ascendance Biotechnology, Inc. (“Ascendance”). Under the Asset Contribution Agreement, Hepregen has agreed to contribute substantially all of its assets and BioTime, ESI and ReCyte Therapeutics have agreed to contribute certain assets and to license certain patents and other intellectual property to Ascendance in exchange for shares of Ascendance common stock. Ascendance will also assume substantially all of Hepregen’s contracts and liabilities and will assume certain liabilities related to the assets contributed by BioTime. Hepregen is engaged in the business of manufacturing and selling proprietary products and services that assay new drug candidates for potential toxicity utilizing liver cells on proprietary test plates. The assets to be contributed and the patents and intellectual property to be exclusively licensed to Ascendance by BioTime, ESI and ReCyte Therapeutics include research products presently sold by BioTime through its ESI-BIO division, and certain technology that Ascendance may use to derive liver cells and cardiomyocytes from BioTime human embryonic progenitor cell lines or ESI human embryonic stem cell lines for use in the drug toxicity assay products and services, as well as products for reserarch purposes, that it plans to market. BioTime and its subsidiaries will initially own a majority of the shares of Ascendance common stock. The transaction is expected to close during November 2015. Upon the close of the Asset Contribution Agreement, BioTime will account for this transaction as a business combination using the acquisition method of accounting in accordance with ASC 805, Business Combinations

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2015
Summary of Significant Accounting Policies [Abstract]
Revenue recognition	Revenue recognition
Cash and cash equivalents	Cash and cash equivalents
Trade accounts and grants receivable, net	Trade accounts and grants receivable, net
Concentrations of credit risk	Concentrations of credit risk
Inventory	Inventory –
Equipment, net and construction in progress	Equipment, net and construction in progress
Intangible assets, net	Intangible assets, net
Treasury stock	Treasury stock –
Warrants to purchase common stock	Warrants to purchase common stock
Cost of sales	Cost of sales
Patent costs	Patent costs –
Reclassification	Reclassification
Research and development	Research and development
General and administrative	General and administrative
Foreign currency translation and other comprehensive loss, foreign currency transaction gains and losses	Foreign currency translation and other comprehensive loss, foreign currency transaction gains and losses – For transactions denominated in other than the functional currency of BioTime, transactional gains and losses are recorded in other income and expense included in the condensed consolidated statements of operations. Foreign currency transaction loss amounted to $430,000 and $353,000, respectively, for the three and nine months ended September 30, 2015, and an $88,000 loss and $92,000 gain, respectively for the three and nine months ended September 30, 2014.
Income taxes	Income taxes – An income tax benefit of approximately $3.4 million was recorded for the nine months ended September 30, 2015, of which approximately $3.6 million of the benefit was related to federal, offset by $214,000 related to state taxes. For the same period in 2014, an income tax benefit of approximately $5.2 million was recorded, of which approximately $3.6 million of the benefit was related to federal and $1.6 million to state taxes. Asterias established deferred tax liabilities primarily related to its acquisition of certain intellectual property. It is more likely than not that the Asterias deferred tax assets are fully realizable since these income tax benefits are expected to be available to offset such Asterias deferred tax liabilities. In June 2014, Asterias sold 5,000,000 BioTime shares that resulted in a taxable gain of approximately $10.3 million and a tax payable of $3.6 million. Asterias received the BioTime shares from BioTime as part of the consideration for the Asterias common stock and warrants issued to BioTime under an Asset Contribution Agreement among BioTime, Asterias, and Geron Corporation, a tax free transaction. This income tax liability was offset by available net operating losses, resulting in no cash income taxes due from that sale. This transaction was treated as a deemed distribution by Asterias and recorded against equity. During the first six months of 2014, OncoCyte sold 86,156 BioTime common shares in open market transactions that resulted in a taxable gain of approximately $300,000. This taxable gain was fully offset by current operating losses, thus resulting in no income taxes due from the sale. A valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. OncoCyte established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. Stock-based compensation –
Stock-based compensation	Stock-based compensation –
Impairment of long-lived assets	Impairment of long-lived assets –
Deferred license fees	Deferred license fees
Loss per share	Loss per share
Fair value of financial instruments	Fair value of financial instruments
Recently issued accounting pronouncements	Recently Issued Accounting Pronouncements In July 2015, the FASB postponed the effective date of the new revenue standard, Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606),” by one year. The new effective date is for fiscal years and interim periods beginning after December 15, 2017. BioTime expects to adopt this guidance when effective and the impact, if any, on its consolidated financial statements is not currently estimable. In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory” that replaces the existing accounting standards for the measurement of inventory. ASU 2015-11 requires a company to measure inventory at the lower of cost and net realizable value. Net realizable value is defined as the “estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation.” The effective date of ASU 2015-11 is for annual reporting periods beginning after December 15, 2016, including interim periods within those annual reporting periods. BioTime does not expect ASU 2015-11 will have a material effect on its consolidated financial statements.

Organization, Basis of Presen20

Organization, Basis of Presentation and Liquidity (Tables)	9 Months Ended
	Sep. 30, 2015
Organization, Basis of Presentation, and Liquidity [Abstract]
BioTime's ownership of outstanding shares of its subsidiaries	The following table reflects BioTime’s ownership, directly or through one or more subsidiaries, of the outstanding shares of its subsidiaries as of September 30, 2015. Subsidiary Field of Business BioTime Ownership Country Asterias Biotherapeutics, Inc. (NYSE MKT: AST) Therapeutic products derived from pluripotent stem cells, and immunotherapy products. Clinical programs include: AST-OPC1 for spinal cord injury, AST-VAC1 for acute mylegenous leukemia, and AST-VAC2 for non-small cell lung cancer 58.0% USA Cell Cure Neurosciences Ltd. Products to treat age related macular degeneration (“AMD”) and neurological diseases. Lead product OpRegen ® 62.5% (1) Israel ES Cell International Pte Ltd Stem cell products for research, including clinical grade cell lines produced under cGMP 100% Singapore LifeMap Sciences, Inc. Biomedical, gene, disease, and stem cell databases and tools 77.9% USA LifeMap Sciences, Ltd. Biomedical, gene, disease, and stem cell databases and tools (2) Israel LifeMap Solutions, Inc. Mobile health software applications (2) USA OncoCyte Corporation (4) Developing proprietary non-invasive, liquid biopsy and diagnostics for lung, breast and bladder cancers 74.9% USA OrthoCyte Corporation Orthopedic diseases and injuries, including bone grafting, chronic back pain and osteoarthritis 100.0% (3) USA ReCyte Therapeutics, Inc. Research and development involved in stem cell-derived endothelial and cardiovascular related progenitor cells for the treatment of vascular disorders, ischemic conditions and brown adipocytes for type-2 diabetes and obesity 94.8% USA (1) Includes shares owned by BioTime, Asterias, and ESI. (2) LifeMap Sciences, Ltd. and LifeMap Solutions, Inc. are wholly-owned subsidiaries of LifeMap Sciences, Inc. (3) Includes shares owned by BioTime and Asterias. (4) See Note 12 regarding OncoCyte’s O ctober 7, 2015, filing of a registration statement on Form 10 with the SEC in connection with BioTime’s planned distribution of shares of OncoCyte common stock to holders of BioTime common shares, on a pro rata basis .

Equipment, net and constructi21

Equipment, net and construction in progress (Tables)	9 Months Ended
	Sep. 30, 2015
Equipment, net and construction in progress [Abstract]
Equipment, furniture and fixtures and construction in progress	At September 30, 2015 and December 31, 2014, equipment, furniture and fixtures, and construction in progress were comprised of the following (in thousands): September 30, 2015 (Unaudited) December 31, 2014 Equipment, furniture and fixtures $ 5,383 $ 4,871 Construction in progress 4,604 406 Accumulated depreciation (3,206 ) (2,419 ) Equipment, net and construction in progress $ 6,781 $ 2,858

Intangible assets, net (Tables)

Intangible assets, net (Tables)	9 Months Ended
	Sep. 30, 2015
Intangible assets, net [Abstract]
Intangible assets	At September 30, 2015 and December 31, 2014, intangible assets were comprised of the following (in thousands): September 30, 2015 (Unaudited) December 31, 2014 Intangible assets $ 52,562 $ 52,562 Accumulated amortization (17,656 ) (13,714 ) Intangible assets, net $ 34,906 $ 38,848

Deferred License Fees (Tables)

Deferred License Fees (Tables)	9 Months Ended
	Sep. 30, 2015
Deferred License Fees [Abstract]
Amortization of deferred license fees	As of September 30, 2015, future amortization of deferred license fees described above was as follows (in thousands): Year Ended December 31, Deferred License Fees 2015 $ 34 2016 125 2017 120 2018 83 2019 34 Thereafter 75 Total $ 471

Accounts Payable and Accrued 24

Accounts Payable and Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2015
Accounts Payable and Accrued Liabilities [Abstract]
Accounts payable and accrued liabilities	At September 30, 2015 and December 31, 2014, accounts payable and accrued liabilities consisted of the following (in thousands): September 30, 2015 (Unaudited) December 31, 2014 Accounts payable $ 1,934 $ 2,297 Accrued expenses 4,729 3,125 Accrued bonuses 804 964 Other current liabilities 326 417 Total $ 7,793 $ 6,803

Organization, Basis of Presen25

Organization, Basis of Presentation and Liquidity (Details) - USD ($) $ in Thousands		1 Months Ended	9 Months Ended
		Oct. 31, 2015	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Noncontrolling Interest [Line Items]
Accumulated deficit			$ (215,757)		$ (182,190)
Shareholders' equity			60,934		62,723
Cash and cash equivalents			29,378	$ 7,416	$ 29,487	$ 5,495
Proceeds from issuance of common shares			8,578	$ 14,724
Subsequent Event [Member]
Noncontrolling Interest [Line Items]
Proceeds from issuance of common shares		$ 20,400
Shares sold (in shares)		6,530,612
Parent [Member]
Noncontrolling Interest [Line Items]
Accumulated deficit			(215,800)
Working capital			24,000
Shareholders' equity			60,900
Cash and cash equivalents			$ 29,400
Parent [Member] | Subsequent Event [Member]
Noncontrolling Interest [Line Items]
Proceeds from issuance of common shares		$ 25,500
Shares sold (in shares)		8,130,612
Asterias Biotherapeutics, Inc. [Member] | USA
Noncontrolling Interest [Line Items]
BioTime's Ownership			58.00%
Cell Cure Neurosciences, Ltd. [Member] | Israel
Noncontrolling Interest [Line Items]
BioTime's Ownership	[1]		62.50%
ES Cell International Pte., Ltd. [Member] | Singapore
Noncontrolling Interest [Line Items]
BioTime's Ownership			100.00%
LifeMap Sciences, Inc. [Member] | USA
Noncontrolling Interest [Line Items]
BioTime's Ownership			77.90%
LifeMap Sciences, Ltd. [Member] | Israel
Noncontrolling Interest [Line Items]
BioTime's Ownership	[2]		0.00%
LifeMap Solutions, Inc. [Member] | USA
Noncontrolling Interest [Line Items]
BioTime's Ownership	[2]		0.00%
OncoCyte Corporation [Member]
Noncontrolling Interest [Line Items]
Shares sold (in shares)		246,356
OncoCyte Corporation [Member] | USA
Noncontrolling Interest [Line Items]
BioTime's Ownership	[3]		74.90%
OrthoCyte Corporation [Member] | USA
Noncontrolling Interest [Line Items]
BioTime's Ownership	[4]		100.00%
ReCyte Therapeutics, Inc. [Member] | USA
Noncontrolling Interest [Line Items]
BioTime's Ownership			94.80%
[1]	Includes shares owned by BioTime, Asterias, and ESI.
[2]	LifeMap Sciences, Ltd. and LifeMap Solutions, Inc. are wholly-owned subsidiaries of LifeMap Sciences, Inc.
[3]	See Note 12 regarding OncoCyte's October 7, 2015, filing of a registration statement on Form 10 with the SEC in connection with BioTime's planned distribution of shares of OncoCyte common stock to holders of BioTime common shares, on a pro rata basis.
[4]	Includes shares owned by BioTime and Asterias.

Summary of Significant Accoun26

Summary of Significant Accounting Policies (Details) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended	9 Months Ended
	Jun. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Jun. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Summary of Significant Accounting Policies [Abstract]
Trade receivable		$ 664,000			$ 664,000		$ 549,000
Grants receivable		280,000			280,000		493,000
Allowance for doubtful accounts		101,000			101,000		$ 101,000
Property, Plant and Equipment [Line Items]
Foreign currency translation gains (losses) included in comprehensive loss		44,000	$ (67,000)		(273,000)	$ (216,000)
Foreign currency transaction gain (loss)		(430,000)	(88,000)		(353,000)	92,000
Income Taxes [Abstract]
Accrued interest and penalties		0	0		0	0
Deferred income tax benefit		$ (948,000)	$ (2,313,000)		(3,395,000)	(5,175,000)
Deferred income tax benefit, federal					(3,600,000)	(3,600,000)
Deferred income tax expense (benefit), state taxes					$ (214,000)	$ (1,600,000)
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life					10 years
Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Equipment useful life					36 months
Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Equipment useful life					120 months
Asterias Biotherapeutics, Inc. [Member]
Income Taxes [Abstract]
Number of shares sold by subsidiary (in shares)	5,000,000
Taxable gain on sale of subsidiary shares	$ 10,300,000			$ 10,300,000
Tax payable on sale of subsidiary shares	3,600,000			$ 3,600,000
OncoCyte Corporation [Member]
Income Taxes [Abstract]
Number of shares sold by subsidiary (in shares)				86,156
Taxable gain on sale of subsidiary shares	$ 300,000			$ 300,000
Licensed Technologies [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life					10 years
Treasury Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from computation of diluted loss per share (in shares)		4,718,942	5,398,542		4,718,942	5,398,542
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from computation of diluted loss per share (in shares)		4,698,064	3,420,068		4,698,064	3,420,068
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from computation of diluted loss per share (in shares)		9,190,782	9,195,002		9,190,782	9,195,002

Inventory (Details)

Inventory (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Inventory [Abstract]
Raw materials and finished goods products on-site	$ 247,000	$ 253,000
Inventory of finished goods held by third party on consignment	$ 13,000	$ 13,000

Equipment, net and constructi28

Equipment, net and construction in progress (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Equipment, furniture and fixtures [Abstract]
Equipment, furniture and fixtures	$ 5,383		$ 4,871
Construction in progress	4,604		406
Accumulated depreciation	(3,206)		(2,419)
Equipment net, and construction in progress	6,781		$ 2,858
Depreciation expense	776	$ 794
Leasehold improvements for Asterias' facility	4,600
Tenant improvement allowance under lease agreement	4,400
Amount qualifying for reimbursement under the tenant improvement allowance	4,100
Amount remaining under lease agreement	300
Reimbursement from landlord on construction in progress	$ 2,564	$ 0

Intangible assets, net (Details

Intangible assets, net (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Intangible assets, net [Abstract]
Intangible assets	$ 52,562		$ 52,562
Accumulated amortization	(17,656)		(13,714)
Intangible assets, net	$ 34,906		$ 38,848
Intangible assets, useful life	10 years
Amortization of intangible assets	$ 3,942	$ 4,104

Deferred License Fees (Details)

Deferred License Fees (Details)	9 Months Ended
	Sep. 30, 2015USD ($)
Amortization of deferred license fees [Abstract]
Intangible assets, useful life	10 years
Licensed Technologies [Member]
Amortization of deferred license fees [Abstract]
2,015	$ 34,000
2,016	125,000
2,017	120,000
2,018	83,000
2,019	34,000
Thereafter	75,000
Total	$ 471,000
Intangible assets, useful life	10 years
Prepaid expenses in other current assets	$ 119,000
Deferred license fees in noncurrent assts	$ 352,000

Accounts Payable and Accrued 31

Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Accounts Payable and Accrued Liabilities [Abstract]
Accounts payable	$ 1,934	$ 2,297
Accrued expenses	4,729	3,125
Accrued bonuses	804	964
Other current liabilities	326	417
Total	$ 7,793	$ 6,803

Commitments and Related Party32

Commitments and Related Party Transactions (Details)	May. 31, 2015USD ($)Investorshares	Sep. 30, 2015USD ($)ft²$ / sharesshares	Jun. 30, 2015USD ($)$ / sharesshares	Apr. 30, 2015USD ($)Investor$ / shares	Feb. 28, 2015USD ($)$ / sharesshares	Jun. 30, 2014USD ($)Investorshares	Sep. 30, 2015USD ($)ft²$ / sharesshares	Sep. 30, 2014USD ($)	Dec. 31, 2014USD ($)shares
Related Party Transaction [Line Items]
Rent per month							$ 5,050
Area of office space (in square feet) | ft²		900					900
Proceeds from issuance of common shares							$ 8,578,000	$ 14,724,000
Principal and accumulated interest							188,000	$ 467,000
Carrying value of convertible notes		$ 255,000					$ 255,000		$ 60,000
Common stock, issued (in shares) | shares		86,764,000					86,764,000		83,122,000
BioTime Common Stock [Member]
Related Party Transaction [Line Items]
Proceeds from issuance of common shares		$ 8,600,000
Shares sold (in shares) | shares		2,607,401
Stock price (in dollars per share) | $ / shares		$ 3.29					$ 3.29
OncoCyte Common Stock [Member]
Related Party Transaction [Line Items]
Payments to Acquire Interest in Subsidiaries and Affiliates		$ 8,350,000
George Karfunkel [Member] | BioTime Common Stock [Member]
Related Party Transaction [Line Items]
Shares sold (in shares) | shares						4,000,000
George Karfunkel [Member] | Asterias Warrants [Member]
Related Party Transaction [Line Items]
Number of shares purchased (in shares) | shares						4,000,000
Broadwood Partners LP [Member] | BioTime Common Stock [Member]
Related Party Transaction [Line Items]
Shares sold (in shares) | shares						1,000,000
Number of shares purchased (in shares) | shares		2,431,611					2,431,611
Asterias Biotherapeutics [Member]
Related Party Transaction [Line Items]
Number of shares purchased (in shares) | shares						5,000,000
Asterias Biotherapeutics [Member] | BioTime Common Stock [Member]
Related Party Transaction [Line Items]
Proceeds from issuance of common shares						$ 12,500,000
Shares sold (in shares) | shares						5,000,000
Number of investors | Investor						2
Asterias Biotherapeutics [Member] | Asterias Warrants [Member]
Related Party Transaction [Line Items]
Proceeds from issuance of common shares						$ 11,700,000
Number of shares purchased (in shares) | shares		1,000,000					1,000,000
Asterias Biotherapeutics [Member] | Series A Common Stock [Member]
Related Party Transaction [Line Items]
Proceeds from issuance of common shares					$ 5,500,000
Shares sold (in shares) | shares					1,410,255
Stock price (in dollars per share) | $ / shares					$ 3.90
Number of shares purchased (in shares) | shares					1,025,640
Cell Cure Neurosciences, Ltd. [Member]
Related Party Transaction [Line Items]
Number of investors | Investor				2
Stated interest rate				3.00%
Conversion price (in dollars per share) | $ / shares				$ 20
Estimated fair market value (in dollars per share) | $ / shares				$ 41
Principal and accumulated interest				$ 471,000
Accrued interest is payable period				3 years
Effective annual interest rate				23.00%
Carrying value of convertible notes		$ 255,000					$ 255,000
Amount of convertible note		676,000					676,000
Unamortized debt discount		$ 421,000					$ 421,000
Cell Cure Neurosciences, Ltd. [Member] | Convertible Notes Payable [Member]
Related Party Transaction [Line Items]
Principal and accumulated interest				$ 188,000
Unamortized debt discount				$ 659,000
OncoCyte [Member] | Subscription Agreements [Member]
Related Party Transaction [Line Items]
Number of investors | Investor	2
OncoCyte [Member] | Second Agreement [Member]
Related Party Transaction [Line Items]
Non-compete Agreement Term			1 year
Fair value of warrants			$ 65,400
OncoCyte [Member] | Second Agreement [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Investor passive ownership threshold			5.00%
OncoCyte [Member] | Investors [Member] | OncoCyte Common Stock [Member] | Subscription Agreements [Member]
Related Party Transaction [Line Items]
Proceeds from issuance of common shares	$ 3,300,000
Common stock, issued (in shares) | shares	3,000,000
OncoCyte [Member] | Investors [Member] | OncoCyte Common Stock [Member] | Second Agreement [Member]
Related Party Transaction [Line Items]
Pre-offer valuation of rights			$ 40,000,000
Maximum purchase price of shares of pre-offer			$ 3,000,000
Number of shares that can be called by warrants (in shares) | shares			3,000,000
Warrants exercise price (in dollars per share) | $ / shares			$ 0.01
OncoCyte [Member] | George Karfunkel [Member] | OncoCyte Common Stock [Member] | Subscription Agreements [Member]
Related Party Transaction [Line Items]
Shares sold (in shares) | shares	1,000,000
OncoCyte [Member] | George Karfunkel [Member] | OncoCyte Common Stock [Member] | Subscription Agreements [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Ownership interest rate	5.00%

Shareholders' Equity (Details)

Shareholders' Equity (Details) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Preferred Shares [Abstract]
Preferred shares, shares authorized (in shares)	2,000,000		2,000,000
Series A convertible preferred stock outstanding (in shares)	70,000		70,000
Promissory notes	$ 363,000
Number of common stock issued for exchange of each common stock held of other company as per option agreement (in shares)	1
Common Shares [Abstract]
Common stock, authorized (in shares)	125,000,000		125,000,000
Common stock, par value (in dollars per share)	$ 0		$ 0
Common shares, shares issued (in shares)	86,764,000		83,122,000
Common shares, shares outstanding (in shares)	82,045,000		78,228,000
Treasury stock (in shares)	4,719,000		4,894,000
Stock options granted (in shares)	1,100,000	1,410,000
Options exercised (in shares)	155,532
Warrants exercised (in shares)	3,897
Proceeds from exercises of stock options	$ 621,000	$ 220,000
Proceeds from exercise of warrants	$ 19,000	$ 0
Series A Preferred Stock [Member]
Preferred Shares [Abstract]
Series A convertible preferred stock outstanding (in shares)	70,000
Share conversion price (in dollars per share)	$ 4
Common stock conversion ratio	12.5
Preferred stock dividend rate	3.00%

Sales of BioTime Common Share34

Sales of BioTime Common Shares by Subsidiaries (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)shares	Sep. 30, 2014USD ($)Investorshares
BioTime Common Stock [Member]
Related Party Transaction [Line Items]
Number of shares sold (in shares)	175,000
Proceeds from sale of BioTime stock | $	$ 576,000
Asterias Biotherapeutics [Member] | BioTime Common Stock [Member]
Related Party Transaction [Line Items]
Number of shares sold (in shares)		5,000,000
Proceeds from sale of BioTime stock | $		$ 12,500
Number of investors | Investor		2
Asterias Biotherapeutics [Member] | Asterias Common Stock [Member]
Related Party Transaction [Line Items]
Number of shares purchased (in shares)		5,000,000

Segment Information (Details)

Segment Information (Details)	9 Months Ended
	Sep. 30, 2015Segment
Segment Information [Abstract]
Number of operating segments	1

Subsequent Events (Details)

Subsequent Events (Details)	Oct. 08, 2015USD ($)	Oct. 08, 2015GBP (£)	Oct. 31, 2015USD ($)$ / sharesshares	Sep. 30, 2015USD ($)shares	Jun. 30, 2014USD ($)shares	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Dec. 31, 2014USD ($)
Subsequent Event [Line Items]
Proceeds from issuance of common shares						$ 8,578,000	$ 14,724,000
Term of license	5 years	5 years
Intrest bearing short-term advance				$ 506,000		506,000		$ 0
OncoCyte Corporation [Member]
Subsequent Event [Line Items]
Sale of stock, number of shares issued in transaction (in shares) | shares			246,356
Common Shares [Member]
Subsequent Event [Line Items]
Sale of stock, number of shares issued in transaction (in shares) | shares				2,607,401
Proceeds from issuance of common shares				$ 8,600,000
Common Shares [Member] | Asterias Biotherapeutics, Inc. [Member]
Subsequent Event [Line Items]
Sale of stock, number of shares issued in transaction (in shares) | shares					5,000,000
Proceeds from issuance of common shares					$ 12,500,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Sale of stock, number of shares issued in transaction (in shares) | shares			6,530,612
Proceeds from issuance of common shares			$ 20,400,000
Purchase price per share (in dollars per share) | $ / shares			$ 3.13
Intrest bearing short-term advance				$ 500,000		$ 500,000
Subsequent Event [Member] | Asterias Biotherapeutics, Inc. [Member]
Subsequent Event [Line Items]
License Costs	$ 6,600,000	£ 4,350,000
Subsequent Event [Member] | Broadwood [Member]
Subsequent Event [Line Items]
Sale of stock, number of shares issued in transaction (in shares) | shares			1,600,000
Proceeds from issuance of common shares			$ 5,100,000
Purchase price per share (in dollars per share) | $ / shares			$ 3.19
Subsequent Event [Member] | Series A Preferred Stock [Member] | Asterias Biotherapeutics, Inc. [Member]
Subsequent Event [Line Items]
License Costs	$ 5,500,000	£ 3,600,000